Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumoulin, Daphne W., Cornelissen, Robin, Bezemer, Koen, Baart, Sara J., Aerts, Joachim G. J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158710/
https://www.ncbi.nlm.nih.gov/pubmed/34069348
http://dx.doi.org/10.3390/vaccines9050525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158710/
https://www.ncbi.nlm.nih.gov/pubmed/34069348
http://dx.doi.org/10.3390/vaccines9050525

Ejemplares similares